The latest tirzepatide news: what's changed, what's coming, and what it means for you

What did the NICE recommendation actually decide, and who does it cover?

NICE published its appraisal of tirzepatide for weight management (TA1026) in December 2024, updated in September 2025, and the recommendation was significant. For NHS use, the guidance covers adults with a BMI of 35 or above and at least one weight-related comorbidity, conditions including type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. For some ethnic backgrounds (South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean), the BMI threshold sits 2.5 kg/m² lower throughout.

The NHS rollout is phased by how many qualifying conditions a person has. From June 2025, those with a BMI of 40 or above plus four or more of the five listed conditions became eligible. The second cohort, covering BMI 35–39.9 with four or more conditions, opened in June 2026. Further phases are expected through 2027. Meeting the criteria does not guarantee a prescription, clinical assessment and participation in wrap-around dietary and activity support are both required. You can read the full eligibility detail in NICE's appraisal of tirzepatide (TA1026).

For people who fall outside these thresholds or who would rather not wait, private treatment through a regulated online pharmacy remains a separate route, subject to the same clinical assessment of individual suitability. The licence itself (for private prescribing) covers adults with BMI 30 or above, or 27 or above alongside a weight-related health condition, and our tirzepatide licence page explains exactly what those licensed indications mean in practice.

What was the SURMOUNT-5 head-to-head trial, and why does it matter?

For years, comparisons between tirzepatide and semaglutide were indirect, inferred from separate trials with different populations. SURMOUNT-5 changed that. Published in the New England Journal of Medicine in 2025, it was a randomised, open-label trial involving 751 adults with obesity but without diabetes, run over 72 weeks, comparing tirzepatide directly with semaglutide 2.4mg. The result: tirzepatide produced greater average weight reduction. That finding informed the discussion in NICE's recommendations chapter for TA1026, which noted that indirect comparisons also favoured tirzepatide.

It is worth saying clearly that "greater average reduction" describes a group result, not a promise for any one person. Individual responses vary based on starting weight, adherence, lifestyle changes alongside treatment, and how well a particular medicine is tolerated. The SURMOUNT-1 trial, which randomised more than 2,500 adults, found average body-weight reductions of around 20–21% at the highest tirzepatide dose over 72 weeks, a figure regularly cited but one that sits at the optimistic end of real-world experience for most people.

If you are weighing tirzepatide against other options, our tirzepatide overview page lays out the mechanism and clinical profile in detail, and our prescribers are well placed to talk through which medicine fits your situation.

What happened with the Mounjaro price increase, and how does it affect people paying privately?

From 1 September 2025, Eli Lilly raised the UK list price of Mounjaro substantially. The highest dose (15mg) moved from around £122 to around £330 per four-week pen, as widely reported in August 2025, and you can find a fuller account of that announcement and its background on our news about Mounjaro page. Lower doses saw smaller increases. This was a manufacturer list-price decision, and it fed through into private provider pricing across the market.

For people paying out of pocket, the shift was material. Private prices for tirzepatide since then typically range roughly £149–£375 a month depending on the dose and the provider. Those figures are hedged because private pharmacies set their own margins, and prices continue to move. What those headline figures sometimes obscure is what they do and do not include: consultation fees, prescription charges, delivery, and ongoing clinical support are all sometimes bundled and sometimes charged separately. If you want honest context on what private treatment costs and what to look for, the Mounjaro cost page covers this in full.

At nume, one price includes the consultation, prescription, treatment, and free next-working-day delivery, tracked by DPD, arriving in plain, unbranded packaging. No subscription, no auto-renewal; every repeat order goes through a fresh clinical review.

What tirzepatide news should I watch for next?

The two developments most worth following are the continuing NHS rollout and any MHRA safety communications. On the NHS side, a third cohort is expected around March 2027, covering adults with BMI 40 or above and three qualifying conditions. GP practices can now prescribe tirzepatide under the 2026/27 GP contract, though participation is optional and availability varies by practice and area, so the picture is uneven across England, and criteria differ further in Scotland, Wales and Northern Ireland.

On the safety side, the MHRA continues to monitor tirzepatide under its Black Triangle (▼) status, which means any new signals are actively tracked and communicated. In January 2026 the regulator issued a Drug Safety Update covering acute pancreatitis as a known but infrequent risk across GLP-1 medicines, patients should seek urgent medical help for severe, persistent stomach pain that radiates to the back. Suspected side effects can be reported at the MHRA's Yellow Card scheme. Our new tirzepatide developments page and the Mounjaro news page are updated as further changes are confirmed.

If you want to talk through any of this with a clinician, rather than sifting press releases yourself, you are welcome to speak to our prescribers, every consultation is reviewed by a GPhC-registered Independent Prescriber the same day, at no cost to you.